Mahmoud Ghazzi

Over the past 25 years, he has held several executive leadership roles that cover the spectrum of Drug Development including President, Global Development Head, Chief Medical Advisor, Medicine Development Center Head, and Therapeutic Area Head. His most recent role was President, Daiichi-Sankyo Pharmaceutical Development, and Global Development Head, Daiichi-Sankyo Research & Development.

Throughout his career, Dr. Ghazzi has developed portfolios, managed drug development pipelines globally, and advised and led therapeutic area strategies, resources, and talents. He has managed team leaders, physicians, scientists, regulatory strategists, and project managers. Dr. Ghazzi has been responsible for several Global Regulatory submissions and participated in regulatory interactions including Advisory Committee Meetings.

At MMS, Dr. Ghazzi supports internal teams and MMS clients with clinical and regulatory strategy and execution particularly in the areas of cardiovascular and metabolic diseases. He provides independent expert advice for Clinical Development, Regulatory, Safety and Pharmacovigilance, and portfolio strategy including support for drug safety monitoring boards. Dr. Ghazzi earned his MD from the School of Medicine at Damascus University in Syria and a MPH degree, as well as a Ph.D. in Bioengineering, from the University of Michigan.

Suggested For You

news

June 19th, 2025

MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and its CEO Named CRO Champion 

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

regulatory intelligence

June 16th, 2025

Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution